get a key
steadybase-$ company QNTM
account_id none on file
legal_name Quantum Biopharma Ltd.
ticker QNTM
cik 1771885
domain quantumbiopharma.com
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
calls 0 filings 12 executives 0 family 0
why_nownone on file
callsnone on file
filings
Carroll was appointed as CFO of the Company effective August 30, 2024. (5) Mr. Coyle resigned from his role as CFO of the Company effective August 30, 2024, and assumed the role of Controller of the Company.

filing / Mar 26, 2026 / receipt

as CFO of the Company effective August 30, 2024, and assumed the role of Controller of the Company. (6) The Non-Equity Incentive Plan Compensation amounts shown for fiscal years 2025 and 2024 relate solely to annual bonuses accrued or paid to Zeeshan Saeed, Anthony Durkacz, and Donal Carroll pursuant to their respective employment agreements.

filing / Mar 26, 2026 / receipt

The Company rents an office space in Toronto, Ontario, Canada. During fiscal year ended 2025, the head office incurred costs of a total amount of approximately C$ 72,300 , including taxes.

filing / Mar 26, 2026 / receipt

Significant reduction in R&D expense in excess of $1M during Q12026.

ir_statement / Sep 15, 2026 / receipt

Operating expenses of $2.3M for the three months ended June 30, 2026, compared to $4.9M for the three months ended June 30, 2025.

ir_statement / Sep 15, 2026 / receipt

Reduction in R&D expense in excess of $1.1M during the six months ended June 30, 2026.

ir_statement / Sep 15, 2026 / receipt

Operating expenses of $2.9M as of March 31, 2026, compared to $3.3M as of March 31, 2025.

ir_statement / Sep 15, 2026 / receipt

Significant reduction in R&D expense in excess of $1M during Q12026.

ir_statement / Sep 15, 2026 / receipt

Significant reduction in R&D expense in excess of $1M during Q12026.

ir_statement / Sep 15, 2026 / receipt

Strong improvements in cash and operating efficiency

ir_statement / Sep 15, 2026 / receipt

General & Administrative $1,320 $1,328

ir_statement / Sep 15, 2026 / receipt

Significant reduction in R&D expense in excess of $1M during Q12026.

ir_statement / Sep 15, 2026 / receipt

executivesnone on file
familynone on file
upcoming
2026-11-06 earnings call scheduled ir
changesnone on file
mcp_package_hint
steadybase-$